Notícias

With a stock price of $3.32, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 10 Unrivaled Penny Stocks to Buy Now. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million. The company ended the quarter with approximately $665.2 million in cash, cash equivalents, and restricted cash, […]

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away from a mixed quarterly earnings print. See our latest analysis for Recursion Pharmaceuticals. At a share price of US$3.27, Recursion’s 30 day share price return of 2.51% sits against a 90 day share price decline of 17.84% and a 1 year total shareholder return of 25.51% loss. This suggests that...

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported key clinical milestones across its AI-driven pipeline, including positive early data for REC-1245. The company initiated a new Phase 1 trial for REC-4539, expanding its early-stage clinical portfolio. REC-4881 achieved Phase 2 success in familial adenomatous polyposis, with active FDA engagement around a potential registrational pathway. Recursion Pharmaceuticals focuses on applying AI-driven drug discovery to build a diversified clinical...

The old healthcare model is breaking down.

Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion reported significant progress across its AI-driven clinical pipeline for Q1 2026, highlighted by positive early data for its RBM39 degrader, REC-1245. In the Phase 1/2 DAHLIA study, the molecule showed a well-tolerated safety profile […]

Najat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.

Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Wondering whether Recursion Pharmaceuticals at around US$3.39 is a bargain or a value trap? This article focuses squarely on what the current share price might be telling you about the business. The stock has been volatile, with a 3.4% decline over the last 7 days, a 9.0% gain over 30 days, and returns of 19.3% lower year to date and 40.5% lower over the past year. These moves come as Recursion Pharmaceuticals continues to attract attention within the biotech space, where investors often...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best fundamentally strong penny stocks to invest in now. On April 30, TheFly reported that JPMorgan trimmed the price target on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from $11 to $10 and reiterated an Overweight rating. With the highest 1-year price target among analysts, the firm’s estimate implies 192.83% upside […]

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.

Recursion Pharmaceuticals (RXRX) closed at $3.3 in the latest trading session, marking a -3.23% move from the prior day.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1-year median price target of $7. This supports a moderately bullish consensus sentiment, with 1 Buy rating and 2 Hold calls. […]